This is placeholder text. To connect this element to content from your collection, select the element and click Connect to Data.
Customization
Integration of ToxGPS, ChemTunes and Corina technology into your chemoinformatics environment
Customization
Integration of ToxGPS, ChemTunes and Corina technology into your chemoinformatics environment
Customization
Integration of ToxGPS, ChemTunes and Corina technology into your chemoinformatics environment
training and consultancy for computational toxicology
ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk
Guidance collection
2021
ICH M7, impurities, genotoxicity, QSAR, read-across
EMA
This guideline emphasizes considerations of both safety and quality risk management in establishing levels of mutagenic impurities that are expected to pose negligible carcinogenic risk. It outlines recommendations for assessment and control of mutagenic impurities that reside or are reasonably expected to reside in final drug substance or product, taking into consideration the intended conditions of human use.